New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2013
08:31 EDTNVAXNovavax says BARDA continues contract for both seasonal, pandemic flu programs
Novavax announced that the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority, or BARDA, has completed an In-Process Review of Novavax' contract covering the company's recombinant virus-like particle vaccine candidates for pandemic and seasonal influenza. The contractually-defined IPR was conducted by a team of U.S. Government experts, who provided input on Novavax' progress during the contract base period and plans for further development, including both near-term process development and manufacturing activities and longer-term clinical efforts. BARDA has notified the company that based on the results of the IPR, a milestone decision has been made to continue the contract for both the seasonal and pandemic influenza programs. In March 2011, Novavax was awarded a contract valued at up to $179M by BARDA for the advanced development of recombinant vaccines for the prevention of seasonal and pandemic influenza. In the midst of the contract's 3-year base period, valued at $97M, Novavax has been developing and testing its novel recombinant virus-like particle influenza vaccines to address BARDA's commitment to advancing recombinant-based technology as a component of pandemic preparedness. The contract can be extended for an additional 24-month option period at BARDA's option, with $82M in additional funding to build on the work Novavax accomplishes during the base period and to support manufacturing scale-up and licensure by the U.S. Food & Drug Administration.
News For NVAX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
09:21 EDTNVAXOn The Fly: Pre-market Movers
Subscribe for More Information
08:39 EDTNVAXNovavax granted FDA fast track designation to RSV F vaccine
Novavax announced that the FDA has granted Fast Track Designation to Novavax' RSV F-Protein nanoparticle vaccine candidate, or RSV F vaccine, for protection of infants via maternal immunization.
November 17, 2014
16:10 EDTNVAXNovavax initiates Phase 2 clinical trial of quadrivalent seasonal influenza VLP
Subscribe for More Information
November 14, 2014
17:14 EDTNVAXNovavax initiates phase 2 clinical trial of RSV vaccine in elderly subjects
Subscribe for More Information
November 10, 2014
08:53 EDTNVAXNovavax initiates Phase 1 clinical trial of RSV F vaccine
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use